Orthopedic outcome studies and cost issues

Louis M. Aledort

doi:10.1055/s-2003-37939

Orthopedic outcome studies and cost issues

Louis M. Aledort

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.

Original language	English
Pages (from-to)	55-60
Number of pages	6
Journal	Seminars in Thrombosis and Hemostasis
Volume	29
Issue number	1
DOIs	https://doi.org/10.1055/s-2003-37939
State	Published - Feb 2003

Keywords

Cost
Factor concentrates
Hemophilia
Orthopedic outcomes
Prophylaxis

Access to Document

10.1055/s-2003-37939

Cite this

@article{3cee7049c0c941d2b2547cefed23f596,

title = "Orthopedic outcome studies and cost issues",

abstract = "Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.",

keywords = "Cost, Factor concentrates, Hemophilia, Orthopedic outcomes, Prophylaxis",

author = "Aledort, \{Louis M.\}",

year = "2003",

month = feb,

doi = "10.1055/s-2003-37939",

language = "English",

volume = "29",

pages = "55--60",

journal = "Seminars in Thrombosis and Hemostasis",

issn = "0094-6176",

publisher = "Thieme Medical Publishers, Inc.",

number = "1",

}

TY - JOUR

T1 - Orthopedic outcome studies and cost issues

AU - Aledort, Louis M.

PY - 2003/2

Y1 - 2003/2

N2 - Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.

AB - Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.

KW - Cost

KW - Factor concentrates

KW - Hemophilia

KW - Orthopedic outcomes

KW - Prophylaxis

UR - https://www.scopus.com/pages/publications/0037325386

U2 - 10.1055/s-2003-37939

DO - 10.1055/s-2003-37939

M3 - Review article

C2 - 12640566

AN - SCOPUS:0037325386

SN - 0094-6176

VL - 29

SP - 55

EP - 60

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

IS - 1

ER -

Orthopedic outcome studies and cost issues

Abstract

Keywords

Access to Document

Fingerprint

Cite this